1. Pink Sheet
  2. >>Market Access

CMS Offers Part D Plans Financial Backstop If Rebates Eliminated In 2020

 
• By Cathy Kelly

But CMS also advises Medicare Part D plans to develop bids for the 2020 plan year that include rebates, since the final version of the HHS rule eliminating the anti-kickback safe harbor for rebates may not be released in time for the June 3 bid submission deadline. 

rebate - cube with letters, sign with wooden cubes

Medicare Part D plans may be able to participate in a “demonstration” over the next two years that would help cushion the financial impact of an HHS rule to eliminate drug rebates by revising the anti-kickback safe harbor that currently protects them.

“If there is a change in the safe harbor rules effective in 2020, [the Centers for Medicare and Medicaid Services]...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.